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Abstract The roles of the melanocortin 3 receptor (MC3-R)
and its agonist, Q2-melanocyte-stimulating hormone (Q2-MSH)
in the regulation of the hypothalamo-pituitary-gonadal (HPG)
axis are poorly understood. Here we show Q2-MSH stimulated
intracellular cAMP accumulation and gonadotrophin-releasing
hormone (GnRH) secretion in the immortalised GnRH cell line
GT1-7. The MC3/4-R antagonist Agrp blocked these actions.
Reverse transcriptase polymerase chain reaction demonstrated
GT1-7 cells express MC3-R mRNA. Q2-MSH also stimulated
GnRH release from hypothalamic explants. In vivo, Q2-MSH
administration into the medial preoptic area signi¢cantly in-
creased plasma luteinising hormone. MC3-R and Q2-MSH may
modulate the HPG axis.
/ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The hypothalamic melanocortin system comprises the me-
lanocortin 3 and 4 receptors (MC3-R and MC4-R), the en-
dogenous MC3/4-R antagonist, agouti-related protein (Agrp)
and the agonists K- and Q-melanocyte-stimulating hormones
(K-MSH and Q-MSH). K-MSH activates MC3-R and MC4-R
equally but Q2-MSH has a higher a⁄nity for MC3-R [1,2].
Whilst MC4-R may modulate energy homeostasis, the role
of MC3-R remains unclear.
Anatomical evidence suggests the melanocortin system may
in£uence reproductive function. MC4-R and MC3-R mRNA
[1,3] and K-MSH [4] and Q-MSH immunoreactivity are found
in the medial preoptic nucleus (MPO), an area rich in gona-
dotrophin-releasing hormone (GnRH) neurones. Pro-opiome-
lanocortin (POMC) neurones synapse directly onto GnRH
neurones [5] and the POMC products, K-MSH and L-endor-
phin have been demonstrated to in£uence gonadotrophin re-
lease (see [6] for review). Arcuate Agrp-containing neurones
also project to the MPO [7]. This suggests GnRH neurones
may be in£uenced by the melanocortin system.
The aims of these studies were to (a) determine whether
K-MSH and Q2-MSH act directly on GnRH neurones; (b)
identify the melanocortin receptor(s) resulting in GnRH re-
lease; (c) examine the e¡ects of K-MSH and Q2-MSH on
GnRH release from hypothalamic explants; and (d) con¢rm
these ¢ndings in vivo by measurement of plasma gonadotro-
phins following MPO injection of K-MSH and Q2-MSH in
male rats.
2. Materials and methods
2.1. Peptides
[Nle4,D-Phe7]-K-MSH (NDP-MSH) (a long-acting synthetic ana-
logue of K-MSH), K-MSH and Q2-MSH were purchased from Bachem
Laboratory plc (St. Helens, Merseyside, UK). Agrp (83^132) was
purchased from Phoenix Pharmaceuticals (Belmont, CA, USA). Other
reagents were purchased from BDH (Poole, Dorset, UK), Gibco
(Renfrewshire, UK) and Sigma (Poole, Dorset, UK).
2.2. Animals
Male Wistar rats (speci¢c pathogen-free, Imperial College, London,
UK) weighing 250^300 g were individually housed under controlled
temperature (21^23‡C) and light (12 h light, 12 h dark) with ad libi-
tum access to food (RM1 diet, SDS UK Ltd, Witham, UK) and
water. Animal procedures were approved by the British Home O⁄ce
Animals Scienti¢c Procedures Act 1986 (project license 90/1077).
2.3. Cell culture
The immortalised murine hypothalamic GnRH neuronal cell line
GT1-7 (donated by Dr P. Mellon, University of California) [8] was
cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM) (Gibco) as
previously described (passage number 26^28) [9]. Cells were cultured
(2.5U105 per well, determined by haemocytometer counts) in 48 well
plates (Nunc International, Roskilde, Denmark) in DMEM and main-
tained for 48 h to reach 90^95% con£uence.
Brie£y, for cAMP determination, cells were preincubated in serum-
free DMEM containing 3-isobutyl-1-methyl-xanthine (IBMX) (2 mM)
(Sigma). The medium was replaced with DMEM and IBMX either
alone, with the test substance(s) or with forskolin (100 WM). After 15
min, the cells were washed and extracted in ethanol. The samples were
dried and the cAMP concentration determined by a cAMP scintilla-
tion proximity assay (Amersham, UK). To assess GnRH release, cells
were preincubated for 2 h in DMEM with 0.1% bovine serum albumin
(Sigma). The medium was replaced with DMEM either alone, con-
taining the test substance(s) or with KCl (59 mM) and incubated for
1 h. The GnRH concentration in the medium was determined by
radioimmunoassay (RIA). All studies were repeated on at least four
occasions.
2.4. Melanocortin receptor expression in GnRH clonal cell lines
Total RNA was isolated from GT1-7 and mouse hypothalami
(n=6) using Trizol reagent (Gibco, Paisley, Renfrewshire, UK) ac-
cording to the manufacturer’s instructions. Twenty micrograms were
reverse-transcribed using avian myoblastoma virus reverse transcrip-
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tase (RT) (Promega, Southampton, UK) in a reaction primed using
oligo(dT). Half of this reaction was subjected to polymerase chain
reaction (PCR) using primers obtained from the published sequence
(mouse MC3-R: X74983, mouse MC4-R: AF201662). Primers were
synthesised by Oswel DNA services (Southampton, UK). The primers
used in the reaction for MC4-R were atactaggtagagacctgc and
aaggctctgatttctgctag and for MC3-R were cgtttctctctggagaaact and
ggatgttttccatcagactg. PCR for mouse GAPDH was performed at the
same time as a control (primers: ctgagtatgtcgtggagtct and tgagctt-
cccgttctgggca). The following concentrations were used in the PCR
mixture: RT mixture 10 Wl, Taq DNA polymerase bu¡er 10 Wl (Sig-
ma), dNTP 2 Wl, 5P primer 1 Wl, 3P primer 1 Wl, Taq DNA polymerase
5 U (Sigma) and glass-distilled water 75 Wl. The conditions used for
the PCR were 95‡C for 45 s, 58‡C for 30 s and 72‡C for 60 s for
30 cycles. Following PCR, 1/50 of the reaction was subjected to a
second round of PCR using internal primers for MC4-R (agaatttat-
cactcaggcac and gaaagaacagggttgactc) and for MC3-R (atctagactgga-
cagcatcc and acgatgcccagtgccaggaa). Using these primers, an ampli-
¢ed fragment of 295 kb for MC4-R and 265 kb for MC3-R would be
expected. Controls treated in an identical way, but with no RT added
to the reverse transcription, were conducted at the same time. All the
PCR reactions were analysed on 1% agarose gels.
2.5. GnRH release from hypothalamic explants
Hypothalami, 1.7 mm thick, were taken parallel to the base of the
brain to include the MPOs. These were maintained in a static incu-
bation system with arti¢cial cerebrospinal £uid (aCSF) equilibrated
with 95% O2 and 5% CO2 as previously described [10]. Following a 2 h
equilibration period, the hypothalami were incubated for three se-
quential 45 min periods in (a) 500 Wl aCSF (basal), (b) 500 Wl test
peptide and (c) 500 Wl 56 mM KCl. Explants not showing release
above basal levels following KCl were excluded. At the end of each
period, the aCSF was removed and frozen at 320‡C until measure-
ment of GnRH by RIA.
2.6. MPO cannulation and injection
Permanent 26-gauge medial preoptic cannulae were implanted as
previously described [11]. Following recovery, the animals were
handled daily and habituated to experimental procedures. All peptides
were dissolved in saline and the injection volume was 0.5 Wl. Correct
cannula placement was con¢rmed histologically. Animals with incor-
rect cannula placement were excluded from the analysis.
The feeding e¡ects of K-MSH and Q2-MSH were used to determine
the dose of Q2-MSH without signi¢cant feeding e¡ects, and therefore
without signi¢cant MC4-R activation, as the appropriate dose for
study of gonadotrophin release. The selected doses of Q2-MSH were
10-fold greater than those of K-MSH based on the relative bindings of
K-MSH and Q2-MSH at MC3-R. Groups of fasted rats (n=10^11)
were injected with saline, K-MSH (0.1 or 0.3 nmol) or Q2-MSH (1
or 3 nmol). Food intake was measured at 1, 4 and 24 h after injection.
Groups of fed rats (n=10^11) were injected with saline, K-MSH
(0.3 nmol) or Q2-MSH (3 nmol) in the early light phase and killed 20
min following injection. Blood was collected into plastic lithium hep-
arin tubes containing 0.6 mg of apoprotinin. Plasma was separated by
centrifugation and stored at 320‡C. Plasma luteinising hormone (LH)
and follicle-stimulating hormone (FSH) were measured by RIA.
2.7. RIA
GnRH levels were measured using reagents and methods kindly
provided by H.M. Fraser, Medical Research Centre Reproductive
Biology Unit, Edinburgh, UK as previously described [12]. Plasma
LH and FSH levels were assayed using reagents and methods pro-
vided by the NIDDK and the National Hormone and Pituitary Pro-
gram (Dr A. Parlow, Harbor University of California, Los Angeles
Medical Center, Los Angeles, CA, USA) as previously described [13].
2.8. Statistical analysis
Results are shown as mean values SS.E.M. Data from clonal cell
line cAMP studies and secretion experiments are expressed as a per-
centage of basal release. Data from hypothalamic explant release ex-
periments were compared by paired t-test between the basal period
and test period. Data from cAMP, secretion and in vivo studies were
compared by analysis of variance with post-hoc Dunnett’s test (Systat,
Evanston, IL, USA) between control and experimental groups. In all
cases, P6 0.05 was considered to be statistically signi¢cant.
3. Results
3.1. Study 1 ^ cAMP accumulation in GT1-7 cells
NDP-MSH dose-dependently increased intracellular cAMP
concentration (Fig. 1a) (cAMP (% basal) : basal 100S 9%,
NDP-MSH (1000 nM) 3131S 727%, P6 0.005). Q2-MSH
also resulted in a dose-dependent increase in intracellular
cAMP concentration (cAMP (% basal) : basal 100S 10%, Q2-
MSH (10 WM) 1398S 403%, P6 0.05) (Fig. 1b). Agrp (100
nM) alone did not alter cAMP accumulation but Agrp 100
nM (100UKi for the MC3/4-R) blocked NDP-MSH and Q2-
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Fig. 1. The e¡ect of (a) NDP-MSH, (b) Q2-MSH and (c) Agrp with
NDP-MSH or Q2-MSH on intracellular cAMP concentrations in
GT1-7 cells. *P6 0.05 v. basal, **P6 0.01 v. basal.
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MSH cAMP accumulation (cAMP (% basal) : basal 100S 7%,
Agrp (100 nM)+Q2-MSH (10 WM) 94S 13%, Agrp (100
nM)+NDP-MSH (10 WM) 132S30%, P=NS) (Fig. 1c).
3.2. Study 2 ^ GnRH release from GT1-7 cells
NDP-MSH dose-dependently increased GnRH secretion
(Fig. 2a) (GnRH release (% basal) : basal 100S 5.9%, NDP-
MSH (1000 nM) 195S 10%, P6 0.01). There was a dose-de-
pendent rise in GnRH release in response to Q2-MSH (GnRH
release (% basal) : basal 100S 6.9%, Q2-MSH (1000 nM)
210S 15%, P6 0.01) (Fig. 2b). Agrp alone did not alter
GnRH release; however, Agrp (100 nM) blocked Q2-MSH
and NDP-MSH stimulated GnRH release (GnRH release
(% basal): basal 100S 2%, Agrp (100 nM)+Q2-MSH (1000
nM) 95S 6%, Agrp (100 nM)+NDP-MSH (1000 nM)
120S 6%, P=NS) (Fig. 2c).
3.3. Study 3 ^ melanocortin receptor expression in GT1-7 cells
RT-PCR ampli¢cation of GT1-7 cell RNA showed no evi-
dence of MC4-R expression. A band of the appropriate size
was visible following PCR using MC3-R-speci¢c primers in
Fig. 2. The e¡ect of (a) NDP-MSH, (b) Q2-MSH and (c) Agrp with
NDP-MSH or Q2-MSH on GnRH release from GT1-7 cells.
*P6 0.05 v. basal, **P6 0.01 v. basal.
Fig. 3. Melanocortin receptor expression in GT1-7 cells. Gel demon-
strating PCR products following ampli¢cation with MC3-R- and
MC4-R-speci¢c primers of GT1-7 cells and murine hypothalamic
RNA with GAPDH as control. M, marker; C, expected size of
MC3-R; D, expected size of MC4-R.
 
 
Fig. 4. The e¡ect of (a) Q2-MSH and (b) Agrp with Q2-MSH on
GnRH release from hypothalamic explants. *P6 0.05 v. basal re-
lease.
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this cell line (Fig. 3). Murine hypothalamic RNA demon-
strated both MC4-R and MC3-R expression.
3.4. Study 4 ^ GnRH release from hypothalamic explants
Q2-MSH signi¢cantly increased hypothalamic GnRH re-
lease, with greatest e¡ect at 1 WM (GnRH release (% basal) :
basal 100S 29%, Q2-MSH (1 WM) 414S112%, P6 0.05) (Fig.
4a). As demonstrated previously [10], Agrp signi¢cantly in-
creased GnRH release (GnRH release (% basal) : basal
100S 19%, Agrp (100 nM) 163S 20%, P6 0.01 (n=15)).
Agrp blocked Q2-MSH-stimulated GnRH release (GnRH re-
lease (% basal) : basal 100S 28%, Agrp (100 nM)+Q2-MSH (10
WM) 129S 20%, P=NS) (Fig. 4b).
3.5. Study 5 ^ plasma gonadotrophins following MPO injection
MPO injection of K-MSH (0.3 nmol) signi¢cantly reduced
1 h food intake but Q2-MSH (3 nmol) had no signi¢cant e¡ect
(1 h food intake: saline 5.0 S 0.3 g, Q2-MSH (3 nmol) 4.4 S
0.4 g, P=NS, K-MSH (0.3 nmol) 3.5 S 0.4 g, P6 0.05). There
was no e¡ect on food intake at later time points. Melanocor-
tin actions on appetite are MC4-R-mediated and thus 3 nmol
Q2-MSH, which does not signi¢cantly a¡ect food intake, was
chosen to investigate the e¡ects of MC3-R activation on go-
nadotrophin release.
MPO administration of Q2-MSH (3 nmol) signi¢cantly in-
creased plasma LH (plasma LH: saline 0.7 S 0.1 ng/ml, Q2-
MSH (3 nmol) 1.0 S 0.1 ng/ml, P6 0.05) (Fig. 5). MPO Q2-
MSH had no e¡ect on plasma FSH (plasma FSH: saline
6.2 S 0.4 ng/ml, Q2-MSH (3 nmol) 6.4 S 0.4 ng/ml, P=NS).
K-MSH (0.3 nmol) had no e¡ect on plasma LH or FSH
(plasma LH: saline 0.7 S 0.1 ng/ml, K-MSH (0.3 nmol)
0.74S 0.1 ng/ml, P=NS; plasma FSH: saline 6.2 S 0.4 ng/
ml, K-MSH (0.3 nmol) 6.4 S 0.3 ng/ml, P=NS).
4. Discussion
The role of the hypothalamic melanocortin system in the
regulation of reproductive function is poorly understood. The
above ¢ndings suggest Q-MSH and MC3-R may play a role.
Both NDP-MSH (MC3/4-R agonist) and Q2-MSH (an ago-
nist with greater selectivity for MC3-R) stimulate cAMP ac-
cumulation and GnRH secretion in the GnRH clonal cell line
GT1-7. The MC3/4-R antagonist Agrp blocks these actions.
Thus both MC3-R and MC4-R agonists act directly on
GnRH cells. This is supported by anatomical evidence dem-
onstrating POMC neurones to synapse directly onto GnRH
neurones [14].
Increases in intracellular cAMP are seen at higher peptide
concentrations than those which increase GnRH release. A
small local rise in cAMP may signi¢cantly increase GnRH
release but would not signi¢cantly increase whole cell cAMP.
However, low concentrations of Q2-MSH may activate an ad-
ditional second messenger system to elicit secretion, such as
has been postulated in the mammolactotroph cell line GH3
[15]. In GH3 cells, Q-MSH increases intracellular calcium con-
centrations in the absence of known melanocortin receptor
mRNA. The MC3/4-R antagonist SHU9119 does not block
this e¡ect. In the GT1-7 cells used here, MC3-R mRNA was
detected and Agrp blocked the e¡ect of Q2-MSH on GnRH
release but this does not exclude the possibility of an addi-
tional novel Q2-MSH receptor.
In this study, MC3-R but not MC4-R mRNA was detected
in the GT1-7 cells. However, Dumont et al. [16] and Khong et
al. [17] have reported detectable MC4-R expression in GT1-7
cells, along with MC3-R expression in the latter study. There
have been con£icting reports for other receptors expressed in
GT1-7 cells such as oestradiol [18,19] and the Q-aminobutyric
acid receptor subtypes [20,21]. Relative receptor expression
levels in GT1-7 cells may be in£uenced by di¡erent clonal
expansion or by environment [22]. It is possible low levels
of MC4-R expression were missed in our study, though it
was repeated on several occasions; however, such low levels
of MC4-R are unlikely to be of biological signi¢cance and it is
therefore likely our results are the consequence of actions via
MC3-R. Our ¢ndings extend previous studies by demonstrat-
ing that not only is MC3-R expressed in GT1-7 cells, but also
that it may mediate the e¡ects of melanocortin agonists on
GnRH release. It would be interesting to con¢rm these ¢nd-
ings in GT1-7 cells over-expressing MC3-R.
The e¡ects of Q2-MSH on GnRH release from hypothalam-
ic explants are similar to those shown in GT1-7 cells. Hypo-
thalamic GnRH release is signi¢cantly increased by Q2-MSH
and Agrp blocks this e¡ect. However, GnRH release is atte-
nuated in response to high concentrations of Q2-MSH result-
ing in a bell-shaped dose^response curve.
The e¡ects of K-MSH and Q2-MSH on gonadotrophin re-
lease were examined in vivo. Melanocortin feeding e¡ects are
thought to be mediated via MC4-R [2]. Q2-MSH (3 nmol) did
not signi¢cantly reduce food intake and probably does not
signi¢cantly bind MC4-R. At this dose, Q2-MSH signi¢cantly
increased plasma LH but K-MSH had no e¡ect. This would
suggest the e¡ects of Q2-MSH on LH are mediated by MC3-R.
There was no e¡ect of MPO area administration of Q2-MSH
Fig. 5. E¡ect of saline, Q2-MSH (3 nmol) or K-MSH (0.3 nmol) in-
jection into the MPO on (a) food intake and (b) plasma LH.
*P6 0.05 v. saline.
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on plasma FSH. Electrophysiological studies have suggested
pituitary FSH release is regulated by the anterior hypothalam-
ic area (AHA) rather than the MPO area [23]. It would be of
interest to determine the e¡ect of Q2-MSH injection into the
AHA on plasma FSH.
Several previous studies have examined the e¡ect of K-MSH
on gonadotrophin release in vivo. Scimonelli et al. [24] dem-
onstrated K-MSH to suppress LH whilst Khorram et al. [25]
showed no e¡ect of K-MSH in ovariectomised females and
Newman et al. [26] reported a stimulation of LH due to K-
MSH. Thus, the LH response to K-MSH appears to di¡er
with administration site and steroid environment. We have
demonstrated that Agrp stimulates GnRH release from hypo-
thalamic explants and also previously shown it increases LH
release in vivo [10]. This would suggest an inhibitory melano-
cortin tone which might be mediated by K-MSH. Since Agrp
has no e¡ect alone on GnRH release from GT1-7 cells and
blocks the stimulatory e¡ect of K-MSH and Q2-MSH, this
stimulatory e¡ect of Agrp is unlikely to be directly at the level
of the GnRH neurone but might be on an inhibitory inter-
neurone.
Rodent and human MC3-R or MC4-R null mutations have
normal fertility and plasma gonadotrophins [27,28]. Develop-
mental compensatory mechanisms may mask the roles of
MC3-R and MC4-R in the hypothalamo-pituitary-gonadal
(HPG) axis. However, there has been no dynamic testing of
the HPG axis in these mice or humans and subtle defects may
not be detected on baseline measurements alone. In contrast,
ubiquitous ectopic expression of the MC4-R antagonist Agou-
ti in Agouti yellow mice (Ay) results in reduced fertility late in
life [29]. Further dynamic examination of the HPG axis in
mice lacking melanocortin receptors or with over-expression
of melanocortin antagonists would be of interest.
Our studies suggest that Q2-MSH stimulates GnRH release
directly from GnRH neurones, increases hypothalamic GnRH
release and gonadotrophin release in vivo. This may suggest a
role for MC3-R in regulation of the HPG axis. Further work
is needed to elucidate the roles of MC3-R and MC4-R in the
HPG axis and there is a particular need for highly selective
melanocortin receptor agonists and antagonists.
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